drugset / Trial / NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566

Phase 4 Not yet recruiting 10 enrolled University of California, San Francisco
NaSingle-groupOpen-labelDevice feasibility

Summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Timeline

Start
2026-08-01
Primary completion
2030-06-01
Completion
2030-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abrocitinib Small molecule
Subject Adalimumab Monoclonal antibody
Subject Apremilast Small molecule
Subject Azathioprine Small molecule
Subject Baractinib Unknown
Subject Bimekizumab Monoclonal antibody
Subject CRAVACITINIB Small molecule
Subject Calcipotriol Small molecule
Subject Certolizumab Protein / enzyme biologic
Subject Chloroquine Small molecule
Subject Crisaborole Small molecule
Subject Cyclosporine Peptide
Subject Dupilumab Monoclonal antibody
Subject Etanercept Protein / enzyme biologic
Subject Guselkumab Monoclonal antibody
Subject Hydroxychloroquine Small molecule
Subject Infliximab Monoclonal antibody
Subject Ixekizumab Monoclonal antibody
Subject Lebrikizumab Monoclonal antibody
Subject Methotrexate Small molecule
Subject Mycophenolate Sodium Unknown
Subject Nemolizumab Monoclonal antibody
Subject Risankizumab Monoclonal antibody
Subject Roflumilast Small molecule
Subject Ruxolitinib Small molecule
Subject Secukinumab Monoclonal antibody
Subject Tacrolimus Small molecule
Subject Tapinarof Other / unclassified
Subject Tildrakizumab Monoclonal antibody
Subject Tofacitinib Small molecule
Subject Tralokinumab Monoclonal antibody
Subject Triamcinolone Other / unclassified
Subject Upadacitinib Small molecule
Subject Ustekinumab Monoclonal antibody
Subject fluorouracil Small molecule

Indications